Calidi Biotherapeutics Q3 2026 net loss attributable to common stockholders narrows 67% to $3.6 million
Calidi Biotherapeutics Q3 2026 net loss attributable to common stockholders narrows 67% to $3.6 mill
Related stories
US Flights to Resume After Air Traffic Network Failure
US flights are set to resume after an air traffic network failure disrupted operations.
M impact | EQUITY | Nov 14, 2026, 08:06 AM UTC
UniCredit Raises $3.5 Billion
M impact | EQUITY | Nov 14, 2026, 08:03 AM UTC
AMAT Shares Fall 2.58% as Headline Cites Record Q4 Revenue
The headline also says 2027 demand is seen above 30%, but provides no further context.
M impact | EQUITY | Nov 14, 2026, 08:02 AM UTC
MSCI to Drop MSTR; CEO Sees Low Impact; $6.8B Bitcoin Loss
M impact | EQUITY | Nov 14, 2026, 08:02 AM UTC
IndiGo Says Global Microsoft Service Disruption Is Fully Resolved
IndiGo said a global Microsoft service disruption affecting its email support services has been fully resolved.
M impact | EQUITY | Nov 14, 2026, 07:36 AM UTC
FAA Tech Failure Grounds Flights for Nearly Five Hours
Air travel ground to a halt for almost five hours Friday after an overloaded air traffic control system failed, snarling operations at Sea-Tac.
M impact | EQUITY | Nov 14, 2026, 07:32 AM UTC